Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cure in Myasthenia Gravis: An Unmet Need.

Muscle & nerve·2026
Same author

Relative frequencies of muscle specific kinase antibody myasthenia in 46 centres worldwide.

Brain : a journal of neurology·2026
Same author

Congenital myasthenic syndrome: is it time for a name change to genetic myasthenic syndrome?

Brain : a journal of neurology·2026
Same author

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.

Journal of neurology·2026
Same author

Formative Research in the Codesign of a Discrete Choice Experiment with Patients with Myasthenia Gravis: Selecting and Refining Attributes, Levels and Scenarios.

The patient·2025
Same author

Clinical utility of autoantibodies in the diagnosis and management of Myasthenia gravis.

Journal of neuroimmunology·2025

Related Experiment Video

Updated: Jul 14, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Current management options in myasthenia gravis.

Stephen Reddel1

  • 1University of Sydney, Departments of Neurology and Molecular Medicine, Clinical Sciences Building, Concord Hospital, NSW 2139, Australia. stephenr@med.usyd.edu.au

Current Allergy and Asthma Reports
|June 6, 2007
PubMed
Summary

Myasthenia gravis is now treatable, but current immunosuppressive therapies have slow responses and significant side effects. Research continues to explore novel treatments and better management of existing therapies for this autoimmune condition.

More Related Videos

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

Related Experiment Videos

Last Updated: Jul 14, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Myasthenia gravis (MG) has transitioned from a fatal condition to a treatable one over the past century.
  • Current treatments for MG, primarily immunosuppressive therapies, are associated with slow response times and significant treatment-induced morbidity and mortality.

Purpose of the Study:

  • To highlight Myasthenia gravis as a model autoimmune disease for testing novel treatments.
  • To emphasize the need for continued research into reinduction of tolerance using animal models.
  • To underscore the importance of understanding current therapies and mitigating their side effects.

Main Methods:

  • Review of historical treatment outcomes for Myasthenia gravis.
  • Discussion of Myasthenia gravis as a model for autoimmune disease research.
  • Exploration of potential therapeutic strategies including reinduction of tolerance.

Main Results:

  • Myasthenia gravis is generally treatable, a significant improvement from its previously fatal nature.
  • Existing chronic immunosuppressive treatments present challenges including slow efficacy and adverse effects.
  • Animal models offer a platform for testing novel tolerance-inducing therapies for autoimmune diseases.

Conclusions:

  • Despite advancements, challenges in Myasthenia gravis treatment persist, necessitating further research.
  • Novel therapeutic approaches and improved management of current treatments are crucial for patient outcomes.
  • Understanding and mitigating treatment side effects remain a key focus in Myasthenia gravis management.